- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01764607
Sirolimus in Kidney Transplant Patients With Squamous Cell Skin Carcinoma
November 9, 2018 updated by: University of Florida
A Phase II Study of Sirolimus in Renal Transplant Patients Diagnosed With New or Recurrent Squamous Cell Skin Carcinoma Currently on Calcineurin-based Immunosuppression.
Solid organ transplant recipients (SOTR) have a 3-5x increased occurrence of cancer in contrast to the general population with basal and squamous cell skin cancer.
The use of immunosuppressant or anti-rejection drugs that are needed after SOTR is known to increase the risk of developing certain kinds of cancer.
The purpose of this study is to find out how well Sirolimus (also known as Rapamune) works at treating squamous cell carcinoma in renal transplant patients.
Study Overview
Detailed Description
This is a Phase II randomized study to evaluate the effectiveness of Sirolimus in treating and preventing squamous cell skin cancer carcinoma using a Simon's 2-stage design.
As part of the study, after the biopsy results of the skin cancer show squamous cell carcinoma and consent had been obtain, the participant will begin taking Sirolimus.
The calcineurin inhibitor (tacrolimus or cyclosporine) will be discontinued once the transplant doctors find that the participants Sirolimus is therapeutic by checking blood tests once a week x 3 weeks.
Approximately 5 weeks after starting Sirolimus, the squamous cell skin cancer will be removed by a surgeon.
Participant next follow up visit for the study is scheduled one year post-operatively.
.The study will look at your squamous cell skin cancer under the microscope to see if sirolimus had any effect at treating your squamous cell skin cancer.
Study Type
Interventional
Enrollment (Actual)
1
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Gainesville, Florida, United States, 32610
- Shands at the University of Florida
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Histologically or cytologically proven squamous cell skin carcinoma
- Recipient of a renal organ transplant at least one year prior to study enrollment
- Receiving a CNI for at least 6 months prior to diagnosis of skin cancer
- No current evidence of graft rejection, except low-grade, chronic graft rejection
- Measurable disease by caliper measurement
- Life expectancy > 6 months
- Age of at least 18 years
- Adequate organ and marrow function as determined by ANC, HGB, PLT, Total Bili, AST, and creatinine clearance
- Ability to understand/willingness to sign a written informed consent form
Exclusion Criteria:
- Inability to give informed consent
- Major surgery within 4 week prior to starting study drug
- Chronic or non-healing open wounds
- Pregnant and nursing women
- Women and men of child-bearing potential must agree to use adequate contraception prior to study entry and for the study duration
- Prior use of an mTOR inhibitor
- Pre-existing clinically significant cardiac, hepatic, pulmonary, or renal dysfunction
- HIV-positive patients
- Proteinuria (> 1 gram)
- Prior or current history of uncontrolled hyperlipidemia (cholesterol > 302 mg/dl or triglycerides 354 mg/dl
- Currently receiving any investigational agents
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to sirolimus (mTOR inhibitors)
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sirolimus treatment
Patients will receive sirolimus 5 weeks prior to removal of squamous cell skin carcinoma.
After the 5 weeks of treatment, nephrology will determine/manage each patient's immunosuppressant therapy.
|
Patients randomized to this arm of the study will receive sirolimus from the time of randomization at least until 5 weeks or the removal of the skin tumor.
Nephrology will determine/manage the immunosuppressant therapy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measure of Squamous Cell Skin Carcinoma in Patients
Time Frame: Baseline, time of surgical removal (5 weeks) and 1 year.
|
Baseline: Measuring of squamous cell skin carcinoma, Week 5: Measuring and surgical removal of squamous cell skin cancer with microscopic evaluation, and in 1 year.
|
Baseline, time of surgical removal (5 weeks) and 1 year.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of Skin Tumor for Squamous Cell Skin Carcinoma
Time Frame: At baseline and time of surgical removal (5 weeks).
|
Tumor will be analyzed at baseline and time of surgical removal by both laboratory and microscopic testing.
|
At baseline and time of surgical removal (5 weeks).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Priya Gopalan, MD, University of Florida
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
April 1, 2013
Primary Completion (Actual)
June 1, 2014
Study Completion (Actual)
June 1, 2014
Study Registration Dates
First Submitted
December 18, 2012
First Submitted That Met QC Criteria
January 7, 2013
First Posted (Estimate)
January 9, 2013
Study Record Updates
Last Update Posted (Actual)
November 14, 2018
Last Update Submitted That Met QC Criteria
November 9, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Carcinoma
- Skin Neoplasms
- Physiological Effects of Drugs
- Anti-Infective Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Anti-Bacterial Agents
- Antibiotics, Antineoplastic
- Antifungal Agents
- Sirolimus
Other Study ID Numbers
- 514-2012
- 00086505 (Other Grant/Funding Number: University of Florida)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Skin Carcinoma
-
City of Hope Medical CenterNational Cancer Institute (NCI); Genentech, Inc.RecruitingLocally Advanced Skin Squamous Cell Carcinoma | Unresectable Skin Squamous Cell Carcinoma | Resectable Skin Squamous Cell CarcinomaUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingSkin Cancer | Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma | Locally Advanced Skin Squamous Cell Carcinoma | Locally Advanced Cutaneous Squamous Cell Carcinoma | Locally Advanced Squamous Cell Carcinoma | Locally Advanced Squamous Cell Carcinoma of the SkinUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)Active, not recruitingMetastatic Skin Squamous Cell Carcinoma | Recurrent Skin Squamous Cell Carcinoma | Locally Advanced Skin Squamous Cell CarcinomaUnited States
-
Falo, Louis, MDNational Cancer Institute (NCI)RecruitingCutaneous Squamous Cell Carcinoma | Skin Cancers - Squamous Cell CarcinomaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingSkin Squamous Cell Carcinoma | Metastatic Skin CancerUnited States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingMetastatic Skin Squamous Cell Carcinoma | Recurrent Skin Squamous Cell CarcinomaUnited States
-
Alpha Tau Medical LTD.CompletedSkin Squamous Cell CarcinomaItaly
-
University of RochesterCompletedSquamous Cell Carcinoma of the Skin
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMetastatic Skin Squamous Cell Carcinoma | Recurrent Skin Squamous Cell CarcinomaUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedCarcinoma, Squamous Cell | Squamous Cell Carcinoma of SkinUnited States
Clinical Trials on Sirolimus
-
Aadi Bioscience, Inc.Approved for marketingTSC1 | TSC2 | PEComa, Malignant | mTOR Pathway Abberation
-
Johns Hopkins UniversityMacuSight, Inc.CompletedPanuveitis | Uveitis | Posterior Uveitis | Intermediate UveitisUnited States
-
Aadi Bioscience, Inc.CompletedHigh Grade Recurrent Glioma and Newly Diagnosed GlioblastomaUnited States
-
Stefan Schieke MDWithdrawnCutaneous T-cell Lymphoma (CTCL)United States
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)CompletedLymphangioleiomyomatosisUnited States
-
Xijing HospitalAir Force Military Medical University, China; Shanghai MicroPort Medical (Group)... and other collaboratorsUnknown
-
The University of Texas Health Science Center,...Society for Pediatric DermatologyCompletedTuberous Sclerosis | Neurofibromatoses | Neurofibroma | AngiofibromaUnited States
-
Paul S Teirstein, MDCordis CorporationCompletedCoronary Artery Disease | Coronary Thrombosis | Coronary RestenosisUnited States
-
Shanghai Jiao Tong University School of MedicineUnknownCoronary Artery DiseaseChina
-
Meril Life Sciences Pvt. Ltd.Lifecare Institute of Medical Sciences and Research Ahmedabad Gujarat IndiaCompleted